INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
SKIN
SUSTAINABILITY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
MEDIA PACK
CONTRIBUTE
Subscribe
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
SKIN
SUSTAINABILITY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
MEDIA PACK
CONTRIBUTE
SEARCH
SEARCH
advanced search
FORMULATION
INJECTION
A Large-Volume and High-Viscosity Autoinjector Delivery Platform for Biotherapeutics
Asmita Khanolkar, Marta Vilaplana, Susanna White and Pete Evans present the Bios platform, designed to simplify device development for the delivery of biologics while maintaining identical key design aspects across all Bios variants.
EXPERT VIEW
GETTING OUT OF A JAM: SUSPENSION DELIVERY, OCCLUSION AND DEVICE DESIGN
Dr Alex Vasiev discusses suspension-based parenteral systems, including micro- and nanoparticle suspensions and colloidal dispersions, where sedimentation, mechanical bridging and interfacial forces can strongly influence delivery performance.
INJECTION
Moritz Mond
Gerresheimer
FROM 3 mL TO 5 mL: EXTENDING AN AUTOINJECTOR PLATFORM FOR LARGER-VOLUME BIOLOGICS
Moritz Mond and Dr Reza Abedian consider the subcutaneous delivery of larger volumes and higher viscosities, sharing the innovative engineering behind the Gx Inbeneo 5 mL autoinjector concept, designed to offer future developers greater flexibility for drug delivery via a handheld device.
INJECTION
Iker Ibisate
RPK Medical
ENGINEERING THE NEXT GENERATION OF AUTOINJECTORS
Iker Ibisate examines the significant potential of springs and stamped metal components to broaden the design space for autoinjector platform developers by condensing an increasing array of key functions into a minimal number of high-precision parts.
SHOWCASE
Lifecore Injectables
MASTERING PRODUCT TRANSFER FOR A RANGE OF INJECTABLES
Lifecore Injectables explores product transfer, the often overlooked step between formulation and filling, and looks at how transfer technologies, mixing and recirculation strategies can be matched to the demands of water-like solutions, highly viscous products and fast-settling suspensions to maintain product quality throughout manufacturing.
FORMULATION
Dr Anders Johansson
Nanexa
PHARMASHELL – AN ALD NANOCOATING TECHNOLOGY FOR ONCE-MONTHLY INJECTABLES
Dr Anders Johansson, Dr Polla Rouf and Dr Oliver Hedge introduce Nanexa’s PharmaShell
®
technology and discuss how, in combination with nanotechnology, it can achieve previously unattainable dosing intervals with standard formulations.
INJECTION
Girum Yemane-Tekeste
Kindeva
AUTOINJECTOR TECHNOLOGY FOR AUTOMATIC MICROPARTICLE SUSPENSION AND INJECTION
Girum Yemane-Tekeste and Stephen Leslie share how Kindeva is building on its experience and history of innovation to develop an enabling technology for injectable microparticles and then evaluating it through proof-of-principle testing.
INJECTION
Martin Junginger
GELITA
INJECTABLE COLLAGEN – PRESENT AND FUTURE POTENTIAL
Martin Junginger discusses the advantages and challenges of delivering collagen via injection, considering the role that collagen plays in the current healthcare landscape, including GELITA's VACCIPRO
®
and MEDELLAPRO
®
collagen grades, and sharing insights on how that role may grow and adapt going forwards.
EARLY INSIGHT
Dr Scott Compel
AEMS Corp
EXCIPIENT LANDSCAPES: HIGH-THROUGHPUT SCREENING TO SOLVE VISCOSITY BOTTLENECKS FOR BIOLOGIC THERAPEUTICS
Dr Scott Compel and Dr Alex Hendricks discuss AEMS Corp's automated, microscale screening platform that enables viscosity reduction, using innovative approaches to test excipient combinations effectively.
EXPERT VIEW
Dr Mehul Desai
ANTIBODY-DRUG CONJUGATES: AN EMERGING FRONTIER IN IV TO SC CONVERSION
Dr Mehul Desai, Dr Michael Hageman and Dr Wei Chen examine the growing antibody-drug conjugate market, the unique formulation challenges these therapies present for subcutaneous delivery and how innovations in on-body injector technology may offer a practical path forwards.
FORMULATION
Dr Liliana Miinea
Lubrizol
FROM BRICK-DUST DRUGS TO BREAKTHROUGHS: TRANSFORMING DRUG DELIVERY WITH NOVEL EXCIPIENTS
Dr Liliana Miinea of Lubrizol discusses how next-generation excipients can help formulators realise the potential of promising but poorly soluble drug candidates, including Lubrizol’s Apisolex™ and Apinovex™ polymer excipients for parenteral and oral applications.
DUAL CHAMBER
Bjørn Knud Andersen
Phillips Medisize
IMPROVING THE SELF-ADMINISTRATION OF LYO- AND LIQUID-LIQUID FORMULATIONS
Bjørn Andersen and Iain Simpson explore the factors contributing to interest in lyo-liquid and liquid-liquid drug delivery, highlighting some of the current unmet needs in this space. Following this, they discuss how platform technologies, such as electromechanical drives, may help address these unmet needs.
EXPERT VIEW
Edward Trappler
FROM HOSPITAL TO HOME HEALTHCARE: ADVANCES IN LYOPHILISED PRODUCT DELIVERY
Edward Trappler, Denise Miller and Michael Thomas discuss the challenges for lyophilised products and consider the role of dual-chamber devices in simplifying reconstitution, particularly for at-home healthcare products, and go on to look at how future advances in delivery devices are providing safe solutions for self-administration while improving patient adherence.
EXPERT VIEW
Jennifer Gattari
MASTERING COMMERCIAL MANUFACTURING FOR STERILE INJECTABLES
Jennifer Gattari delves into what is required to succeed at the commercial phase of sterile injectable manufacturing, going on to explore the challenges that companies can expect and the critical strategies that can help ensure a smooth and scalable journey to market.
INTERVIEW
Pascal Halbherr
InnoMedica
Interview: Pharmapack Start-up Spotlight: InnoMedica Accelerating Trials with Novel Nanoparticle Filling
Pascal Halbherr discusses the InnoMedica's innovative nanocarrier filling technology platform, its impact on biotech and drug delivery, and the company’s bold vision for the future. InnoMedica, a Swiss biotech, is one of the 28 early-stage companies presenting cutting-edge innovations in Pharmapack Europe 2025’s Start-up Market.
EXPERT VIEW
Kyle Toole
DEFINING HIGH-VISCOSITY, LARGE-VOLUME DRUG DELIVERY SYSTEMS
Kyle Toole, Blair Hutton and James McLusky discuss the value that mathematical modelling can provide in the early stages of injectable drug delivery device development, especially when coupled with appropriate empirical testing in a laboratory setting.
EXPERT VIEW
Dr Alex Vasiev
THROUGH THICK AND THIN: MODELLING THE DELIVERY OF NON-NEWTONIAN FORMULATIONS
Alex Vasiev explores the challenges inherent in understanding flow rates in injectable drug delivery when dealing with non-Newtonian fluids, and provides an overview of how to calculate flow rates for power law, Carreau and Cross fluids.
INJECTION
Dr Michael Adler
ten23 health
TRANSITIONING FROM VIAL TO SUBCUTANEOUS INJECTION DEVICES FOR BIOLOGICAL DRUG PRODUCTS
Michael Adler, Venkata Appa Reddy Goli, Andrea Allmendinger and Hanns-Christian Mahler, discuss the various factors that need to be considered when transferring to a delivery device for subcutaneous injection, such as a prefilled syringe or autoinjector, during clinical trials or post-launch, especially when transferring from a vial format for intravenous infusion.
EXPERT VIEW
Tom Oakley
Sanner Group
DRUG DELIVERY TRENDS FOR 2024
Tom Oakley and Kamaal de Silva consider how keeping abreast of the latest trends can help the industry predict and prepare for the future and, commenting from Springboard's privileged position at the centre of many of the drug delivery sector’s most exciting developments, discuss the top trends to look out for in 2024.
FORMULATION
Asmita Khanolkar
SMC Ltd
AN ENABLING AUTOINJECTOR TECHNOLOGY FOR DELIVERY OF LONG-ACTING INJECTABLES
Asmita Khanolkar and Susanna White explain why SMC Ltd's Vita autoinjector with resuspension technology provides a potential solution for the delivery challenges of long-acting injectables.
EXPERT VIEW
David DeSalvo
IDENTIFYING AND OVERCOMING THE CHALLENGES OF INJECTABLE COMBINATION PRODUCT EVOLUTION
David DeSalvo considers some potential challenges that the rapid evolution of autoinjectors (and combination product injectables in general) raises, along with how the industry can successfully address this cycle of reinvention.
INDUSTRIALISATION
Dr Ben Knappett
Particle Works
HIGH-THROUGHPUT SCREENING TO ACCELERATE NANOMEDICINE DISCOVERY
Ben Knappett discusses how the successful combination of microfluidics with automation can provide rapid and cost-effective high-throughput lipid nanoparticle technology formulation screening, and how this approach could play a significant role in advancing the development of new nanotherapies.
WEARABLES
Paolo Golfetto
Stevanato Group
DEVELOPING AN ON-BODY PLATFORM FOR EFFECTIVE POST-OPERATIVE PAIN MANAGEMENT
Paolo Golfetto and Sheldon Moberg discuss a collaboration between Stevanato Group and Bexson Biomedical that meets an urgent unmet patient need.
EXPERT VIEW
Jeff Lowe
SINGLE USE SYSTEMS – THE FUTURE OF BIOPHARMACEUTICAL PROCESSING
Jeff Lowe considers single-use systems and looks at their role in the future of biopharmaceutical processing.
FORMULATION
Dr Steven Prestrelski
Xeris Pharmaceuticals
XERIJECT™: NON-AQUEOUS FORMULATIONS FOR SC INJECTION OF ULTRA-HIGH-CONCENTRATION BIOLOGICS
Steven Prestrelski introduces the XeriJect non-aqueous formulation technology that creates formulations with visco-elastic properties, opening the door to subcutaneous injection of difficult-to-formulate biologics, such as monoclonal antibodies, at very high concentrations.
EXPERT VIEW
Dr Anna Cifuentes-Rius
EXTRACELLULAR VESICLE ENGINEERING: OPTIMISING NATURE’S NON-IMMUNOGENIC, DRUG DELIVERY PLATFORM
Anna Cifuentes-Rius discusses the exciting potential of extracellular vesicles to advance drug delivery, in particular their natural ability to carry API payloads across difficult-to-traverse biological barriers.
1
2
3
Next
Top
